Tegafur-gimeracil-oteracil potassium
Based on 1 Customer Validation
Tegafur-gimeracil-oteracil potassium (S-1; TS-1) is an orally active anticancer agent composed of Tegafur (HY-17400), Gimeracil (HY-17469), and Oteracil potassium (HY-17511). Tegafur-gimeracil-oteracil potassium inhibits the proliferation, migration and invasion of endometrial cancer cells and induces apoptosis by blocking the PI3K/AKT/mTOR signaling pathway. Tegafur-gimeracil-oteracil potassium can be used in research related to endometrial cancer and gastric cancer with peritoneal metastasis.
For research use only. We do not sell to patients.
- Purity: 99.96%
- CAS No.: 150863-82-4
- Formula: C17H15ClFKN6O9
- Molecular Weight:540.89
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Tegafur-gimeracil-oteracil potassium (1-50 μg/mL; 6-48 h) significantly inhibits the viability of Ishikawa and HEC-1-A endometrial cancer cells in a dose- and time-dependent manner, with corresponding IC50 values of 16.26 μg/mL and 11.33 μg/mL for the two cell lines, respectively[1].
Tegafur-gimeracil-oteracil potassium (5-50 μg/mL; 24-72 h) inhibits the proliferation of Ishikawa and HEC-1-A endometrial cancer cells in a concentration-dependent manner[1].
Tegafur-gimeracil-oteracil potassium (5-50 μg/mL) reduces DNA synthesis capacity and proliferative activity of Ishikawa and HEC-1-A endometrial cancer cells in a concentration-dependent manner[1].
Tegafur-gimeracil-oteracil potassium (5-50 μg/mL; 24 h) inhibits the migration of Ishikawa and HEC-1-A endometrial cancer cells in a dose-dependent manner[1].
Tegafur-gimeracil-oteracil potassium (5-50 μg/mL; 24 h) inhibits the invasion of Ishikawa and HEC-1-A endometrial cancer cells in a dose-dependent manner[1].
Tegafur-gimeracil-oteracil potassium (5-50 μg/mL) promotes apoptosis of Ishikawa and HEC-1-A endometrial cancer cells in a concentration-dependent manner[1].
Tegafur-gimeracil-oteracil potassium (10-25 μg/mL) upregulates the mRNA expression of the pro-apoptotic protein Bax and downregulates the mRNA expression of the anti-apoptotic protein Bcl-2 in Ishikawa and HEC-1-A endometrial cancer cells[1].
Tegafur-gimeracil-oteracil potassium (10-25 μg/mL) upregulates the expression of the pro-apoptotic Bax protein and downregulates the expression of the anti-apoptotic Bcl-2 protein in Ishikawa and HEC-1-A endometrial cancer cells[1].
Tegafur-gimeracil-oteracil potassium (25 μg/mL) inhibits the PI3K/AKT/mTOR signaling pathway by reducing the phosphorylation levels of PI3K, AKT and mTOR in Ishikawa and HEC-1-A endometrial cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human endometrial cancer Ishikawa, HEC-1-A cell lines
-
Concentration:5, 10, 25 and 50 μg/mL
-
Incubation Time:24, 48 and 72 h
-
Result:Significantly suppressed proliferation of both cell lines in a concentration-dependent manner.
Caused greater reduction in absorbance at 450 nm over time with higher concentrations.
-
Cell Line:human endometrial cancer Ishikawa, HEC-1-A cell lines
-
Concentration:5, 10, 25 and 50 μg/mL
-
Incubation Time:24 h post-scratch
-
Result:Significantly inhibited migration of both cell lines in a dose-dependent manner.
Exerted the strongest inhibitory effect on wound closure at 50 μg/mL.
-
Cell Line:human endometrial cancer Ishikawa, HEC-1-A cell lines
-
Concentration:5, 10, 25 and 50 μg/mL
-
Incubation Time:24 h
-
Result:Markedly inhibited invasion of both cell lines in a dose-dependent manner.
Caused the greatest reduction in the number of invading cells at 50 μg/mL.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 150863-82-4
-
Appearance Solid
-
Molecular Weight 540.89
-
Formula C17H15ClFKN6O9
-
Color White to off-white
-
SMILES
O=C(C1=NC(NC(N1)=O)=O)O[K].O=C2C=C(C(Cl)=CN2)O.O=C3NC(N(C4OCCC4)C=C3F)=O
-
Synonyms
S-1; TS-1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : 5.56 mg/mL (10.28 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Si Y, et al. TS-1 inhibits endometrial cancer cell proliferation, migration, and apoptosis by blocking the PI3K/AKT/mTOR signaling pathway. Am J Transl Res. 2025;17(10):8312-8323. Published 2025 Oct 25. [Content Brief]
[2]. Osugi H, et al. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination. Oncol Rep. 2002;9(4):811-815. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.8488 mL | 9.2440 mL | 18.4880 mL | 46.2201 mL |
| 5 mM | 0.3698 mL | 1.8488 mL | 3.6976 mL | 9.2440 mL | |
| 10 mM | 0.1849 mL | 0.9244 mL | 1.8488 mL | 4.6220 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Tegafur-gimeracil-oteracil potassium Related Classifications
HY-16441 Related Classifications
Powered by Bioz